jab-3068
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 23, 2018 (NCT03518554)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Protein-tyrosine phosphatase 2CINHIBITOR
PTPN11 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC(=O)N1CC(F)(F)c2c(Sc3ncc(N4CCC5(CC4)COC[C@H]5N)nc3N)cccc21- Mol. weight
- 476.55 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5095185 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04721223 | Phase 1/Phase 2 (Phase 2) | Apr 26, 2021 | AbbVie, Jacobio Pharmaceuticals Co., Ltd. |
| NCT03565003 | Phase 1 | Oct 31, 2018 | Chinese Academy of Medical Sciences, Jacobio Pharmaceuticals Co., Ltd. |
| NCT03518554 | Phase 1 | Apr 23, 2018 | Jacobio Pharmaceuticals Co., Ltd. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jacobio Pharmaceuticals Co., Ltd. | For profit | 3 | 3 | 2 | 2018 |
| AbbVie | For profit | 1 | 0 | 1 | 2021 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2018 |
3 organizations
Page 1 / 1